Neon Therapeutics Shares Are Flashing Brightly after Reporting Predictive Cancer Breakthrough
Source: Streetwise Reports  (9/6/19)
After announcing publication in the scientific journal Immunity that it had created a 61-fold improvement process for predicting cancer-specific antigens, Neon Therapeutics' stock has traded wildly today, up more than 46% at times on nearly 100-times average daily volume, but has since pulled back greatly. More >

FDA Accepts NDA for Global Blood Therapeutics' Sickle Cell Drug; Shares Up 14%
Source: Streetwise Reports  (9/5/19)
Shares of Global Blood Therapeutics are trading more than 14% higher after the FDA accepted its New Drug Application filing for Voxelotor, a drug used in the treatment of sickle cell disease. More >

Coverage Initiated on 'Biotech Machine'
Source: Streetwise Reports  (9/4/19)
The compelling reasons behind those descriptors are explored in a Dawson James Securities report. More >

Topline Results from Lipid-Lowering Trial 'Just What the Doctor Ordered'
Source: Streetwise Reports  (9/4/19)
The study data and their implications are provided in a BTIG report. More >

Ardelyx's Shares Soar 65% as Tenapanor Phase 3 Study Hits the Mark
Source: Streetwise Reports  (9/3/19)
Clinical-stage specialized biopharmaceutical company Ardelyx announced positive results today for its phase 3 AMPLIFY study for tenapanor aimed at improving treatment for cardiorenal diseases. More >

Lannett Signs Exclusive U.S. Distribution Deal with Sinotherapeutics; Shares Up 40%
Source: Streetwise Reports  (8/28/19)
Shares of Lannett Co. are up 40% today after announcing that it secured rights to be the exclusive U.S. distributor of Sinotherapeutics' antifungal drug that is an AB-rated generic for Noxafil. More >

FDA Approves First-of-Its-Kind, Adult Pneumonia Antibiotic; September Launch Planned
Source: Streetwise Reports  (8/27/19)
The drug's features and its developer's commercial plans are discussed in an H.C. Wainwright & Co. report. More >

After Biotech Dives Deeper Into Melanoma Data, It 'Continues to Impress'
Source: Streetwise Reports  (8/27/19)
Details from this clinical program are discussed, along with Q2/19 earnings and the next stock catalyst, in an H.C. Wainwright & Co. report. More >

Why Provention Bio Is in My Portfolio
Source: Daniel Carlson for Streetwise Reports  (8/23/19)
Orphan drug and breakthrough therapy status, which could mean this company's lead candidate is on the FDA fast track, translates to huge opportunities for both those suffering from diabetes and investors, says Daniel Carlson of Tailwinds Research. More >

Retrophin Shares Fall 30% on Failed Phase 3 FORT Study
Source: Streetwise Reports  (8/22/19)
Shares of Retrophin fell to a 52-week low on the news that topline results from its fosmetpantotenate Phase 3 FORT Study for PKNA treatment failed to meet expectations. More >

'Data Readouts Approaching in Two Pivotal Trials' for Biopharma Targeting Unmet Needs
Source: Streetwise Reports  (8/20/19)
The next steps for each of the programs are outlined in a Dawson James Securities report. More >

Analyst Upgrade Ignites Duchenne's Muscular Dystrophy Research Firm's Shares
Source: Streetwise Reports  (8/16/19)
Solid Biosciences' shares are up by more than 40% today after Chardan Capital Markets upgraded the firm's shares from "neutral" to "buy" and raised its price target from $7.50 to $10.00/share. More >

Deciphera's Shares Open 115% Higher on Phase 3 Ripretinib Results
Source: Streetwise Reports  (8/13/19)
Deciphera Pharmaceuticals announced positive top-line results from the INVICTUS pivotal phase 3 clinical study of ripretinib in patients with advanced gastrointestinal stromal tumors. More >

Biotech's DMD Therapeutic 'Solidifies the Ground for Potential Pivotal Design'
Source: Streetwise Reports  (8/12/19)
The latest development concerning this clinical asset and other Q2/19 highlights are provided in an H.C. Wainwright & Co. report. More >

Amgen Shares React Favorably to Enbrel Patent Case Victory
Source: Streetwise Reports  (8/12/19)
Amgen shares are trading 5–6% higher today on news that the company has won its Enbrel (etanercept) patent court case. More >

Puma Biotech Shares Up More Than 20% on Q2 Earnings and Breast Cancer Drug Sales
Source: Streetwise Reports  (8/9/19)
Shares in Puma Biotechnology are trading 20% higher today after the company released Q2/19 earnings and reported positive NERLYNX revenue growth. More >

Avedro Shares Looking Up 35% with Glaukos Merger
Source: Streetwise Reports  (8/8/19)
Avedro Inc. and Glaukos Corp. announced that the firms' boards of directors have executed a definitive merger agreement. The all-stock deal is expected to close in Q4/19. More >

Guardant Health Reports Quarterly Revenue Up 178%
Source: Streetwise Reports  (8/7/19)
Guardant Health Inc. reported strong growth for Q2/19 versus the same period last year and raised its full-year 2019 revenue guidance to $180–190 million. More >

Allakos Shares Double on AK002 Phase 2 Results and Earnings
Source: Streetwise Reports  (8/5/19)
Allakos Inc. shares are soaring today as the company reported Q2/19 earnings and announced positive results from its phase 2 study for its AK002 inhibitor used in the treatment of eosinophil and mast cell related diseases. More >

Gaia Grow Corp. Plants 1,494 Acres of Hemp in Canada and Plans First Harvest in 2 Months
Source: Peter Epstein for Streetwise Reports  (8/1/19)
Gaia Grow Corp. CEO Frederick Pels speaks with Peter Epstein of Epstein Research on the day his company begins trading on the TSX Venture Exchange. More >

Led by Sales of HETLIOZ, Vanda Increases Quarterly Revenues by 25%
Source: Streetwise Reports  (8/1/19)
Shares of Vanda Pharmaceuticals traded nearly 30% higher after the company released Q2/19 earnings and positive sales trends for both HETLIOZ and Fanapt. More >

EMA Opinion Bodes Well for Biopharma's Drug Getting Orphan Status
Source: Streetwise Reports  (7/31/19)
The designation, opinion and asset are discussed in a ROTH Capital Partners report. More >

Mylan Gets a Shot in the Arm with Pfizer Merger Deal
Source: Streetwise Reports  (7/29/19)
EpiPen manufacturer Mylan N.V. announced that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. More >

Anixa Licenses Another Potential Blockbuster
Source: Daniel Carlson for Streetwise Reports  (7/24/19)
Daniel Carlson of Tailwinds Research discusses a major collaboration with the Cleveland Clinic for his top pick stock of the year. More >

Edwards Lifesciences Gets a Charge on Positive Q2 Earnings Report
Source: Streetwise Reports  (7/24/19)
Edwards Lifesciences is trading higher after reporting higher than expected adjusted earnings for Q2/19. The company estimates that the FDA will approve its SAPIEN 3 valve and SAPIEN 3 Ultra system in Q3/19. More >